Published in Antimicrob Agents Chemother on March 26, 2012
The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea. BMC Infect Dis (2017) 0.75
Phenotypic Detection and Antibiogram of β-lactamase-producing Proteus Species in a Tertiary Care Hospital, India. Ann Med Health Sci Res (2017) 0.75
Genome Sequences of Two Multidrug-Resistant Proteus mirabilis Strains Harboring CTX-M-65 Isolated from Malaysia. Genome Announc (2016) 0.75
The Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the Evidence. Infect Dis Rep (2017) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect (2011) 17.47
The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest (1991) 16.06
Management of sepsis. N Engl J Med (2006) 9.01
Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest (1999) 7.40
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol (2001) 4.19
Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother (2005) 3.87
Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. Drug Resist Updat (1998) 3.59
Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother (2007) 3.44
β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis (2011) 3.40
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. Antimicrob Agents Chemother (2009) 3.09
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother (2007) 2.97
The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis (2003) 2.92
"Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis (2004) 2.48
Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev (2008) 2.45
Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother (2006) 2.07
Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob Agents Chemother (2002) 1.88
Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. Int J Antimicrob Agents (2000) 1.83
Reduction of inappropriate urinary catheter use at a Veterans Affairs hospital through a multifaceted quality improvement project. Clin Infect Dis (2011) 1.79
The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol (2005) 1.77
Antibiotic-selective environments. Clin Infect Dis (1998) 1.65
Epidemiology and outcome of nosocomial bloodstream infection in elderly critically ill patients: a comparison between middle-aged, old, and very old patients. Crit Care Med (2009) 1.64
Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin Microbiol Infect (2009) 1.63
Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2005) 1.55
Emerging extended-spectrum beta-lactamases in Proteus mirabilis. J Clin Microbiol (2002) 1.54
Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother (2010) 1.47
Trends among pathogens reported as causing bacteraemia in England, 2004-2008. Clin Microbiol Infect (2011) 1.44
Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn Microbiol Infect Dis (2010) 1.35
Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother (2008) 1.33
Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother (2011) 1.29
Evolution and spread of a multidrug-resistant Proteus mirabilis clone with chromosomal AmpC-type cephalosporinases in Europe. Antimicrob Agents Chemother (2011) 1.28
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother (2008) 1.27
A nosocomial outbreak of infections due to multiply resistant Proteus mirabilis: role of intestinal colonization as a major reservoir. J Infect Dis (1979) 1.20
Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints. J Clin Microbiol (2011) 1.17
Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents (2010) 1.08
Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates. J Clin Microbiol (2006) 1.07
Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagn Microbiol Infect Dis (2002) 1.07
Extended-spectrum beta-lactamases in long-term-care facilities. Clin Microbiol Infect (2008) 1.04
Characterization of a new extended-spectrum beta-lactamase (TEM-87) isolated in Proteus mirabilis during an Italian survey. Antimicrob Agents Chemother (2002) 1.04
Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase. J Antimicrob Chemother (2007) 1.03
Prevalence and epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS multicenter study. Diagn Microbiol Infect Dis (2011) 1.03
Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int J Antimicrob Agents (2008) 1.03
Proteus mirabilis bacteremia: a review of 176 cases during 1980-1992. Scand J Infect Dis (1994) 0.99
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect (2011) 0.97
Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents (2006) 0.92
Urinary tract infections caused by multi-drug resistant Proteus mirabilis: Risk factors and clinical outcomes. Infection (2009) 0.90
Molecular epidemiology of ESbetaL producing P. mirabilis strains from a long-term care and rehabilitation facility in Italy. New Microbiol (2007) 0.81
Prosthetic joint infection: recent developments in diagnosis and management. J Infect (2010) 4.96
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med (2014) 3.56
Detection and Isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn's disease in Sardinia. Am J Gastroenterol (2005) 3.47
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother (2007) 2.97
Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents (2007) 2.61
Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother (2005) 2.48
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis (2012) 2.34
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis (2010) 2.32
Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis (2003) 2.23
Rv1818c-encoded PE_PGRS protein of Mycobacterium tuberculosis is surface exposed and influences bacterial cell structure. Mol Microbiol (2004) 2.09
Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother (2006) 2.07
Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol (2007) 1.99
Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother (2007) 1.91
Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J Antimicrob Chemother (2006) 1.88
Mycobacterium avium subsp. paratuberculosis, genetic susceptibility to Crohn's disease, and Sardinians: the way ahead. J Clin Microbiol (2005) 1.82
Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother (2010) 1.80
Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AIDS (2003) 1.77
Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog (2009) 1.76
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir Ther (2013) 1.66
Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol (2003) 1.58
Direct maldi-tof mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol (2011) 1.58
The quest for a new vaccine against tuberculosis. J Infect Dev Ctries (2009) 1.55
Recurrent ventriculoperitoneal shunt infection caused by small-colony variants of Staphylococcus aureus. Clin Infect Dis (2005) 1.53
Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (2002) 1.52
Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J Leukoc Biol (2009) 1.51
Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother (2010) 1.47
Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum beta-lactamase detection method. J Clin Microbiol (2003) 1.46
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy. AIDS Res Hum Retroviruses (2011) 1.45
Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother (2009) 1.40
Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index. Crit Care (2011) 1.38
Hemangiomas and other congenital malformations in infants exposed to antiretroviral therapy in utero. JAMA (2004) 1.38
Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica (2010) 1.36
Comparative evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry systems for identification of yeasts of medical importance. J Clin Microbiol (2013) 1.36
Use of the VITEK 2 system for rapid identification of clinical isolates of Staphylococci from bloodstream infections. J Clin Microbiol (2003) 1.36
PE is a functional domain responsible for protein translocation and localization on mycobacterial cell wall. Mol Microbiol (2007) 1.34
Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. J Clin Microbiol (2007) 1.33
In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother (2012) 1.29
Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother (2011) 1.29
Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infect Dis (2009) 1.28
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother (2008) 1.27
Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One (2012) 1.27
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology (2010) 1.26
The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol Microbiol (2008) 1.26
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis (2012) 1.26
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care (2014) 1.25
Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol Microbiol (2003) 1.25
Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med (2006) 1.25
Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med (2013) 1.24
Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection. PLoS One (2012) 1.23
Humoral immune responses of type 1 diabetes patients to Mycobacterium avium subsp. paratuberculosis lend support to the infectious trigger hypothesis. Clin Vaccine Immunol (2007) 1.22
Expression and purification of recombinant methylated HBHA in Mycobacterium smegmatis. FEMS Microbiol Lett (2004) 1.21